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Plasmapheresis and Vasculitis Affecting the Kidney 
Tom N Choi, MD 
 
Since the first recorded plasmapheresis in 1914, the process of removing a patient’s 
plasma as a therapeutic treatment has expanded to multiple fields in medicine.  
Plasmapheresis, the isolated removal of blood plasma (the extracellular component of blood), 
was originally developed for patients with Waldenstrom’s disease to reduce serum viscosity.  
Shortly thereafter, therapeutic plasma exchange (TPE) was developed.  In TPE the removed 
plasma is replaced with either a colloid (fresh frozen plasma, cryoprecipitate) or a combination 
of crystalloid and colloid (5% albumin) solutions.  TPE was utilized during World War II, 
resuscitating soldiers that underwent traumatic injuries, allowing replacement of coagulation 
factors while maintaining an isovolemic status.  In 1959, Dr. Michael Rubinstein utilized fresh 
blood exchange transfusion to treat thrombotic thrombocytopenic purpura (TTP) an immune-
related disorder characterized by anti-ADAMTS13 antibodies and associated loss of 
ADAMTS13 activity.1  The loss of functional ADAMTS13 results in the formation of unusually 
large von Willebrand factor remaining expressed on the endothelial cell leading to platelet 
clumping and activation, microthrombi formation, and hemolytic anemia.  Ultimately, it was 
discovered that the isolated removal of plasma removed the ADAMTS13 antibody and the 
replacement with fresh frozen plasma provided the patient with functional ADAMTS13 stopping 
the disease process.  In addition to TTP treatment, plasmapheresis and TPE can be used to 
treat other immune-related disorders.  TPE should be utilized if there is a potential therapeutic 
benefit of removing intravascular substances such as harmful antibodies, complement 
components, other proteins, or toxins/poisons.  The choice of fluid to simultaneous replace the 
volume of the removed plasma depends on the therapeutic goal of the replacement fluid.  If a 
functional enzyme or coagulation factor needs to be replaced then exchange with FFP is most 




MECHANISM AND DETAILS OF PLASMAPHERESIS 
To accomplish plasmapheresis, there are two commonly used modalities - centrifugation 
and filtration.2 In centrifugation plasmapheresis, whole blood is spun into four separate 
components of blood based on their densities (red blood cells, white blood cells, platelets and 
plasma).  In filtration plasmapheresis, the whole blood is passed through a filter and separated 
based on their size.  Generally, the extracorporeal blood volume is limited to 15% of total blood 
volume to limit hypovolemia and circulatory collapse.  Assuming no equilibration with 
extravascular stores and no further production of plasma, approximately 37% of the previous 
plasma remains at the end of 1 plasma volume exchange.  Subsequently, 22% remains after 
1.5 plasma volume exchange and 14% of previous plasma remains after a 2 plasma volume 
exchange.  Anticoagulant agents such as citrate are used to inhibit the coagulation cascade, 
maintaining patency of the extracorporeal system during the procedure. 
The clinical application of plasmapheresis in treatment can be divided in two general 
categories – (1) in acute settings where an active immune-mediated process is causing rapid 
clinical deterioration, and (2) in chronic diseases where there are ongoing pathogenic 
autoantibodies being produced.  As plasmapheresis does not directly treat the underlying 
pathology, therefore its role in the management of chronic diseases is often controversial.   
Potential clinical sequelae must be considered when evaluating the addition of 
plasmapheresis as a treatment option.  Despite best efforts to prevent complications, 
plasmapheresis is not without risk.  The use of regional citrate anticoagulation to maintain circuit 
patency can cause citrate-induced hypocalcaemia and metabolic alkalosis.  It depletes 
coagulation factors and immunoglobulins.  Furthermore, plasmapheresis can remove prescribed 
drugs- affecting a drug’s pharmacokinetics/dynamics, and potentially compromising its 
therapeutic benefit.  If the replacement fluid is with FFP or another blood product, reactions 





Plasmapheresis is a viable treatment option for many complex illnesses with a wide array of 
presentations and cellular variability.  Plasmapheresis for immune-mediated, small-vessel 
vasculitis affecting the kidneys has been reported to be a successful therapy.  However, 
outcomes have been variable and there is evolving concern in the interpretation of the clinical 
studies due to the lack of consistency in treatment patterns.  Therefore clinicians continue to 
individualize care as no evidence based treatment guidelines have been developed.  This 




Small-vessel vasculitides are caused by inflammation of arterioles, capillaries, and 
venules, and include the following diseases: Granulomatosis with Polyangiitis (formerly, 
Wegner’s), Churg-Strauss syndrome, Microscopic polyangiitis, and Henoch-Schonlein Purpura.  
The three former conditions are also referred to as antineutrophil cytoplasmic antibody (ANCA)- 
associated vasculitides.  The pathophysiology of these conditions is not completely understood 
though ANCA is documented to play a role in activating cytokine-primed neutrophils and 
monocytes to target vessel walls.  Additionally, it is thought that cell-mediated immune 
responses play a vital role in granulomatosis with Polyangiitis and Churg-Strauss syndrome due 
to findings of increased T-cell numbers and the presence of granulomas.   
 
TREATMENT 
Multiple randomized controlled studies examined the efficacy of plasmapheresis in 
treating ANCA-mediated renal injury.  Jayne et al., conducted a global study comparing plasma 
exchange to high-dose methylprednisolone as adjunctive therapy for severe renal vasculitides.3  
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Their study consisted of adult patients who presented with a serum creatinine greater than 
5.8mg/dL and a new diagnosis of ANCA-associated systemic vasculitis.  Out of 137 patients, 70 
individuals received seven plasma exchanges while the remaining 67 individuals received 
intravenous methylprednisolone.  Both groups received oral cyclophosphamide and oral 
prednisolone.  The study illustrated that at 3 months, 33 of 67 (49%) individuals that received IV 
methylprednisolone compared with 48 of 70 (69%) individuals that received plasmapheresis 
were alive and independent of dialysis (their primary end point).  Additionally, there was a 24% 
difference in progression to ESRD between the two subsets of patients (43% in 
methylprednisolone group patients versus 19% in plasmapheresis group).  Furthermore, a 
meta-analysis by Walsh et al. identified 9 trials with a total of 387 patients.4  The pooled relative 
risk of end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma 
exchange compared to the standard therapy alone (95% confidence interval 0.65 to 0.99; 
p=0.04).  In a retrospective review of patients with diffuse alveolar hemorrhage (DAH) 
associated with ANCA-associated small-vessel vasculitis, DAH resolved with apheresis in 20 of 
20 patients with average of 6.4 treatments.5  
Daily exchanges should only be considered in fulminant cases or with pulmonary 
hemorrhages to balance the risks of treatment as noted above.  Lastly, standard replacement 
fluid should be with albumin unless pulmonary hemorrhage is present, or if there are concerns 
for coagulopathy.    
 
CONCLUSION 
In summary, the pioneering studies for plasmapheresis in the treatment of small-vessel 
vasculitides support plasma exchange as an adjunctive treatment if the patient is ANCA 
positive.  By using plasmapheresis with the standard therapy such as cyclophosphamide and 
prednisolone, studies have shown a decrease in the development of end-stage renal disease.6-8  
Although there is a small risk of morbidity and mortality (0.3% severe events, mostly associated 
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with cardiac or respiratory etiology).  The current data support plasmapheresis in certain 
circumstances (acute severe deterioration of kidney function; DAH).  However, further studies 
are needed to formulate if plasmapheresis is therapeutic for all patients with ANCA positive 
vasculitis.  As well as define the most appropriate pattern and duration of plasmapheresis.  The 
results from the PEXIVAS- Plasma Exchange and Glucocorticoid Dosing in the Treatment of 
anti-Neutrophil Cytoplasm Antibody Associated Vasculitis a randomized controlled trial are 
eagerly awaited with results expected before 2019.   Finally, there is very limited information 
utilizing TPE for small vessel vasculitides that are ANCA negative.  As a result, further studies 
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